Yoshiharu Mizui

President

2019 - Current

We established Eisai Innovation Inc. in August 2019 and I became the President of the company. We opened offices in Cambridge and San Fransisco. We are seeking for collaboration and investment opportunity for healthcare areas mainly neurology and oncology related therapeutics, diagnosis, and digital solutions.

Head of Business Development group, Strategy department, Oncology business group

2016 - 2019

Director

2011 - 2016

I joined H3 Biomedicine as of April 1st in 2011 and came to work at Cambridge site on June 7th, 2011. Initial role was to establish biology lab at 300 Technology Square. I supported designing the lab and purchase biology equipment and set up the lab. After setting up the lab, I started spliceosome modulator project based on the knowledge of splicing area at Eisai and try to expand the expertise in oncology drug discovery by splicing modulation.

Senior Director

2009 - 2011

As a head of lead discovery biology in Next generation Core Function Unit, I led the the areas of target validation, assay development, target compound profiling, and HTS with 18 FTEs and 6 contractors/consignees. As of April 1st in 2010, my role was expanded to cover lead discovery biology group in Andover, and I had the opportunity to lead a bigger organization with more than 30 people combined both Tsukuba and Andover group members (28 FTEs and 8 contractors/consignees).

Director

2008 - 2009

As a head of Screening Technology group, I led HTS group members with 7 FTE and 3 contractors.

Principal Scientist

2002 - 2008

Joined in oncology group and led E7107 project from scratch to clinical stage. During the period, we identified SF3b as the target molecule of the compound。